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Abstract
Little is known about the origin of the neuroactive steroids
dehydroepiandrosterone sulphate (DHEAS) and preg-
nenolone sulphate (PregS) in the brain or of their subsequent
metabolism. Using rat brain perfusion in situ, we have found
3H-PregS to enter more rapidly than 3H-DHEAS and both to
undergo extensive (> 50%) desulphation within 0.5 min of
uptake. Enzyme activity for the steroid sulphatase catalysing
this deconjugation was enriched in the capillary fraction of the
blood–brain barrier and its mRNA expressed in cultures of rat
brain endothelial cells and astrocytes. Although permeability
measurements suggested a net efﬂux, addition of the efﬂux
inhibitors GF120918 and/or MK571 to the perfusate reduced
rather than enhanced the uptake of 3H-DHEAS and 3H-PregS;
a further reduction was seen upon the addition of unlabelled
steroid sulphate, suggesting a saturable uptake transporter.
Analysis of brain fractions after 0.5 min perfusion with the 3H-
steroid sulphates showed no further metabolism of PregS
beyond the liberation of free steroid pregnenolone. By
contrast, DHEAS underwent 17-hydroxylation to form
androstenediol in both the steroid sulphate and the free
steroid fractions, with some additional formation of
androstenedione in the latter. Our results indicate a gain of
free steroid from circulating steroid sulphates as hormone
precursors at the blood–brain barrier, with implications for
ageing, neurogenesis, neuronal survival, learning and
memory.
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Neuroactive steroids have a variety of actions within the
central nervous system (CNS), and include the so-called
neurosteroids, synthesised within this tissue. The ﬁrst
proposed neurosteroid was dehydroepiandrosterone sulphate
(DHEAS; Corpechot et al. 1981) but although enzymes are
known which will catalyse the synthesis of this steroid (see
Fig. 6), its origins in the CNS remain an enigma. Thus, early
attempts to demonstrate activity in rat brain of the steroid
17a-hydroxylase/c17,20-lyase enzyme (EC 1.14.99.9;
CYP17), which converts the precursor pregnenolone (Preg)
to DHEA, were without success and this enzyme could not
be detected by immunostaining of brain tissue sections (see
Baulieu and Robel 1990; Le Goascogne et al. 1991). Indeed,
further studies suggested the CYP17 mRNA and protein was
only transiently expressed in rat brain during fetal develop-
ment, although it persisted in adult dorsal root ganglia
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(Compagnone et al. 1995) and neither CYP17 mRNA nor
enzyme activity could be detected in adult human brain
(Steckelbroeck et al. 2004). On the other hand, low levels of
CYP17 mRNA have been reported in adult rat (Stromstedt
and Waterman 1995) and human (Yu et al. 2002) brain and
both CYP17 mRNA and enzyme activity detected in
astrocytes and neurons cultured from neonatal rat cerebral
cortex (Zwain and Yen 1999). More recent studies have
shown the expression of CYP17 mRNA, immunoreactivity
and enzyme activity in adult rat spinal cord (Kibaly et al.
2005) and brain, where it is localised to the hippocampus
(see Hojo et al. 2011). There is also the suggestion that
DHEA may arise in brain through a CYP17 independent
pathway involving the reduction of sterol hydroperoxides
(Prasad et al. 1994), although it is not established how such a
mechanism could operate normally in vivo. Notwithstanding
the above ambiguities in the synthesis of DHEA within the
CNS, the 3b-hydroxysteroid sulphotransferase enzyme (EC
2.8.2.2) which would catalyse its sulphation to DHEAS
displays only low or non-detectable activity in adult rat
(Rajkowski et al. 1997) or human (Steckelbroeck et al.
2004) brain. Also, treatment of adult mice with systemic
doses of DHEA sufﬁcient to cause a 30-fold increase in the
concentration of this steroid in the brain had no signiﬁcant
effect on the concentration of DHEAS (Young et al. 1991).
Thus, sulphation of endogenous DHEA is thought unlikely to
be the source of DHEAS within the brain.
The origin of DHEA and DHEAS in the brain remains an
important question because the latter is the major circulating
steroid in the adult primate, where it declines with age
(Orentreich et al. 1984; Campbell 2006) and is thought to act
as a precursor for biologically active hormone in a variety of
peripheral tissues, a form of intracrinology (see Labrie et al.
1995; Reed et al. 2005; Starka et al. 2015). Moreover, both
DHEAS and DHEA are known to have actions on the CNS.
Thus DHEAS has been shown to act as an antagonist at the
GABAA receptor and an agonist at r-receptors (see Maninger
et al. 2009; Starka et al. 2015), albeit at concentrations likely
to exceed those found normally in the adult rat brain (Ebner
et al. 2006). No speciﬁc receptor has been identiﬁed for
DHEA, but animal studies have shown peripheral adminis-
tration of this steroid or its likely precursor DHEAS to be
neuroprotective against a variety of insults, including the
stress hormone corticosterone (Karishma and Herbert 2002),
and to promote neurogenesis and neuronal survival (see
Maninger et al. 2009). Many animal studies have also shown
administration of DHEA or DHEAS to enhance learning and
memory (see Sujkovic et al. 2012) and although these effects
have not consistently been repeated in human subjects (see
Maninger et al. 2009; Starka et al. 2015), supplementation
with DHEA(S) to ameliorate depression and improve cogni-
tive function in elderly or demented subjects with lower
DHEAS/cortisol ratios (Herbert 1998) remains a possibility
(Grimley Evans et al. 2006; Samaras et al. 2013).
Early investigations of brain DHEAS uptake in monkeys
(Knapstein et al. 1968) showed injection of this steroid in the
carotid artery to give rise to more free steroid than
sulphoconjugate in the cerebral cortex and later studies in
humans found a signiﬁcant correlation between the concen-
trations of free DHEA in CSF and DHEAS in serum
(Kancheva et al. 2010). Working in rats, Kishimoto and
Hoshi (1972) reported intracardiac injection of 3H-DHEAS
to result in nearly 50% of the radiolabel accumulating as free
steroid in the brain, as compared to only 5% after intracere-
bral injection, suggesting desulphation before or during
passage through the blood–brain barrier (BBB).
In view of the above, we hypothesised that DHEAS was
taken-up and metabolised at the BBB and tested this by
direct perfusion of the adult rat brain with the steroid
sulphate in a saline-based solution in situ, in order to
eliminate any complications of metabolism in blood or
peripheral tissues. We employed male rats to avoid ﬂuctu-
ations in brain steroid concentrations during the ovarian
cycle (Corpechot et al. 1997). For comparison, we also
investigated the uptake and metabolism of the less well-
studied pregnenolone sulphate (PregS) which is also neu-
roactive, in particular as an antagonist of the GABAA
receptor, a potentiator of the NMDA receptor and an agonist
at r-receptors (see Vallee et al. 2001; Monnet and Maurice
2006) and which on desulphation would give rise to
pregnenolone, the precursor to all known steroid hormones
(see Miller and Auchus 2011). Our results indicate rapid and
extensive de-esteriﬁcation of steroid 3b-sulphates at the
BBB.
Methods
Materials
Chemicals of analytical grade were from Sigma-Aldrich Chemical Co.
(Poole, Dorset, UK) or VWR (Lutterworth, Leicestershire, UK). The
formerwas the sourceof aryl sulfatase, TypeH1fromHelix pomatia and
someunlabelled reference steroid standards; otherswere fromSteraloids
Inc. (Newport, RI, USA). Ethanol, ethyl acetate and isooctane were
redistilled before use. Of the radiolabelled chemicals, [14C]-sucrose
(22.8 GBq/mmol; 615 mCi/mmol) was from Amersham Biosciences
(Little Chalfont, Buckinghamshire, UK) whilst [methyl-3H]-diazepam
(3052.5 GBq/mmol; 82.5 Ci/mmol), [1,2,6,7-3H]-dehydroepiandros-
terone (3422.5 GBq/mmol; 92.5 Ci/mmol) and [7-3H]-pregnenolone
(777.0 GBq/mmol; 21 Ci/mmol) were from PerkinElmer LAS Ltd.,
Beaconsﬁeld, Buckinghamshire, UK, as were Soluene, Solvable and
HiSafe Optiphase 2. The Ecoscint H was from National Diagnostics,
Hessle, Yorkshire, UK. The GF120918 (Elacridar; 9,10-dihydro-5-
methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-iso-
quinolinyl)ethyl]phenyl]-4-acridine-carboxamide hydrochloride) was
a gift from K Read (GlaxoSmithKline, Ware, Hertfordshire, UK) and
MK571 (3-[[[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl][[3-
(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid) from
Alexis Corporation (UK) Ltd (Nottingham, UK). Hypnorm (fentanyl
citrate 0.315 mg/mL and ﬂuanisone 10 mg/mL) came from Janssen
Animal Health (High Wycombe, Buckinghamshire, UK), Hypnovel
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(midazolam 5 mg/mL) from Roche Products (Welwyn Garden City,
Hertfordshire, UK) and heparin from Leo Laboratories (Hurley,
Berkshire UK). The Oasis Hydrophobic-Lipophilic Balance (HLB)
and Mixed-Mode Anion Exchange (MAX) cartridges came from
Waters Corporation, Milford, MA, USA and the Silica gel 60 coated
thin layer chromatography (TLC) plates fromVWR.The imaging ﬁlm
was BAS-TR2040S from Raytek Scientiﬁc Ltd., Shefﬁeld, South
Yorkshire, UK. Silanised glassware was used throughout and unless
stated otherwise, all samples dried down under oxygen-free nitrogen.
Sulphation of steroids
The 3H-Preg and 3H-DHEA were sulphated as described by Dusza
et al. (1968) and then cleaned by procedures given in Corsan et al.
(1997). In brief, 3H-steroids were dried down and redissolved in
10 lL chloroform. Solid triethylamine sulphur trioxide was added
in excess and the reaction mixture left for 2 h at 45°C. For cleaning,
reaction mixtures were dried down, redissolved in 2 mL of 5 mM
sodium phosphate buffer, pH 7 and washed three times with an
equal volume of isooctane to remove remaining free steroid. Solid
sodium chloride was then added to 20% w/v and the steroid
sulphates extracted three times with an equal volume of ethyl
acetate. Finally, the steroid sulphates were puriﬁed by celite
chromatography in isooctane:tert-butanol:water:ammonia (20 : 40 :
39 : 1, v/v). The radioactive fractions were pooled, dried down
under vacuum and redissolved in ammoniated ethanol. Yields of the
initial steroid sulphation reactions and purity of the ﬁnal products
could be estimated by TLC in ethyl acetate:ethanol:ammonia
(25 : 10 : 2, v/v). Positions of the 3H-steroids and their sulphate
esters were visualised with a phosphorimager and in both systems
corresponded to non-radioactive standards (50 lg) run on neigh-
bouring lanes and stained with I2 vapour. Measurement of the
relative densities of the spots corresponding to the 3H-steroids and
their sulphate esters gave estimates for the yields of the initial
sulphation reaction > 94% and for the purity of the ﬁnal product
> 99% (see Fig. S1).
Brain perfusion in situ
All animal experiments were carried out under Home Ofﬁce Project
Licence PPL/5224 according to the UK Animals (Scientiﬁc
Procedures) Act 1986, The European Directive for the Protection
of Animals used in Scientiﬁc Procedures 2008 and the Arrive
Guidelines (www.nc3rs.org.uk/arrive-guidelines). Brain perfusions
were performed using a modiﬁed short-duration technique (Takasato
et al. 1984). Brieﬂy, male Wistar rats purchased from Harlan (now
Envigo; Resource Identiﬁer RRID:RGD_10401918), Bicester, UK
(age 6–8 weeks; body weight range 225–365 g) were anaesthetised
by an intra-peritoneal injection (2.7 mL/kg) of water:Hypnorm:
Hypnovel, 2 : 1 : 1, v/v. Each animal also received intraperitoneal
heparin, 10 000 U/kg. Body temperature was maintained at 37°C
with a heating pad.
Hemi-perfusions of the right hemisphere were carried out via the
right common carotid artery (Youdim et al. 2004). Perfusions were
performed using a pre-oxygenated (95% O2, 5% CO2), ﬁltered and
saline-based solution containing (in mM) 117 NaCl, 4.7 KCl, 24.8
NaHCO3, 1.2 KH2PO4, 2.5 CaCl2, 0.8 MgSO4, 10 HEPES and 10
D-glucose, pH 7.4, at 37°C. For analysis of free and sulphated
steroids and for steryl-sulfate sulfohydrolase (EC 3.1.6.2; trivial
name steroid sulphatase) assays, both hemispheres were perfused,
via right and left common carotid arteries, and 0.8 mM MgCl2
replaced 0.8 mM MgSO4 in the solution. The perfusate was
delivered at a constant rate of 6 mL/min for hemi-perfusions and
12 mL/min for bilateral perfusions, maintaining a net perfusion
pressure of 40–70 mm Hg.
Sample collection and analysis
On completion of the perfusion, the animal was decapitated for rapid
removal of the brain. The meninges and choroid plexus were
stripped away, the hindbrain cut off and the remaining brain divided
into right and left hemispheres. The perfusion and subsequent
processing of the brain samples followed one of three procedures
given below.
1. Uptake of 3H-steroid
The saline-based solution containing 0.5 lCi (0.0185 MBq)/mL
3H-labelled DHEAS (5.4 nM) or PregS (23.8 nM) was used for
hemi-perfusions of up to 1.0 min. Inﬂuence of efﬂux transporters on
uptake was assessed by adding 3 lM GF120918 and/or 50 lM
MK571 directly to the perfusate, and co-perfusing them with the test
compound, as in the protocol of (Cisternino et al. 2003a). In
additional perfusions, saline containing the impermeant marker 14C-
sucrose (0.1 lCi (0.0037 MBq)/mL; 162.6 nM) was used to
determine the intravascular space, or saline containing 3H-diazepam
(1.0 lCi (0.037 MBq)/mL; 12.1 nM), which shows ﬂow-limited
uptake, to measure the ﬂow rate of cerebral perfusate.
Samples (≤ 50 mg) were taken from 7 regions of the right brain
(cerebellum, cortex, hippocampus, hypothalamus, striatum, superior
colliculus, and medulla). The remaining tissue of the right
hemisphere was homogenised and samples (~50 mg) taken in
triplicate (“remainder samples”). Triplicate samples of the perfusate
were also taken. Samples were weighed into vials and dissolved
(48 h at 20C) in 0.5 mL Solvable before addition of 4.5 mL
Optiphase 2 scintillation ﬂuid for counting of radioactivity.
2. Extraction and separation of free and sulphated 3H-steroids
Brains were bilaterally perfused for 0.5 min with 3H-labelled
DHEAS 1.25 or 6.0 lCi (0.046 or 0.221 MBq)/mL (13.5 or
64.9 nM) or PregS 1.0 lCi (0.037 MBq)/mL (47.6 nM). The
hindbrain was removed and each hemisphere homogenised in 2
vols (w/v) buffer containing (in mM) NaCl 141, KCl 4, NaH2PO4 1,
CaCl2 2.8, MgCl2 1, HEPES 10, D-glucose 10, pH 7.4. A sample of
the homogenate of the whole right hemisphere was removed for
scintillation counting, and the remainder retained as the whole brain
homogenate.
The left hemisphere homogenate was separated into capillary-
enriched and capillary-depleted fractions by the method of Triguero
et al. (1990). For this, an equal volume of 26% dextran (w/w)
solution was added to the homogenate and a sample taken for liquid
scintillation counting before centrifugation at 5300 g for 15 min at
4°C. The upper layer was taken as the capillary-depleted fraction
and the pellet as the capillary-enriched fraction.
Before extraction, fractions were sonicated in 5 vols ice-cold,
5 mM potassium phosphate buffer, pH 7. Small portions (150 lL)
were removed for measurement of protein content (Bradford 1976)
and total radioactivity. For the latter, homogenate was solubilised
(15 min, 20C) in 10 vols Soluene then bleached (2 h, 50°C) with
0.3 vol hydrogen peroxide before counting in Ecoscint H containing
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Triton X-100 (6% v/v), glacial acetic acid (0.6% v/v) and butylated
hydroxytoluene (2% w/v). The remainder of each homogenate was
extracted as described in detail elsewhere (Ebner et al. 2006;
Sujkovic et al. 2009), to give free steroid and steroid sulphate
fractions. First, homogenates were extracted into 20 vols ethanol
containing acetic acid 3% (v/v). After centrifugation (28 000 g,
30 min, 25°C) to remove denatured protein, the extracts were
delipidated by partitioning three times against 10 vols isooctane.
Extracts were dried down under vacuum and redissolved in ethanol,
which was then diluted to 20% v/v in 5 mM potassium phosphate
buffer, pH 7.0 at a total volume of 20 ml. Separation of free and
sulphated steroids was achieved by passage through a 60 mg Oasis
MAX cartridge. After washing the cartridge with 5 mL ethanol at
20% v/v in ammonium acetate (20 mM, pH 7), free steroids were
eluted in 4 mL ethyl acetate. Passage of 20 mL ethanol at 60% v/v
in formate/pyridine buffer (20 mM, pH 3) eluted any steroid
glucuronides present. Finally, steroid sulphates were eluted in
30 mL 60% v/v ethanol containing ammonium carbonate 1% (w/v).
To measure the radioactivity of each fraction, portions were dried
down and then redissolved in Ecoscint H for counting. The
remainder was dried down, redissolved in ethanol 96% v/v and
stored at 20°C for subsequent analysis by TLC.
For the analysis of 3H-steroid metabolites, samples were spotted
onto TLC plates for chromatography in the following solvent
systems: A (for sulphated steroids), ethyl acetate:ethanol:ammonia
(5 : 5 : 1, v/v); B (for free steroids) cyclohexane:n-butyl acetate
(1 : 2, v/v); C (for acetylated steroids), isooctane:ethyl acetate
(13 : 7, v/v). Non-radioactive steroid standards could be visualised
by exposure to iodine vapour whereas the 3H-steroids were detected
by placing the TLC plates in contact with imaging ﬁlm for
subsequent visualisation in a phosphorimager. Additional analysis
of the steroid sulphates employed elution from the TLC plate in
ammoniated ethanol then drying down and redissolving in sodium
acetate buffer, 0.5 M, pH 5.0 for desulphation by incubation with
Helix sulphatase (1 mg/mL, 40°C overnight followed by 55°C for
3 h). The resulting free steroids were adsorbed onto a 60 mg Oasis
HLB cartridge and eluted in 5 mL ethyl acetate. This eluate was
dried down and analysed by TLC as above for free steroids. Further
identiﬁcation of 3H-steroid metabolites was obtained by acetylating
them alongside both 3H-labelled and non-radioactive standards. The
TLC eluates or standards were dried down and redissolved in
200 lL pyridine. An equal volume of acetic anhydride was then
added followed by incubation at 37°C for 2 h. The reaction was
stopped by the addition of 1 mL water and the steroids extracted
three times with 1 mL ethyl acetate before drying down for TLC and
visualisation of both 3H-labelled and non-radioactive standards as
described above.
3. Assay of steroid sulphatase
Brains were bilaterally perfused for 2 min. The hindbrain was
removed and the right hemisphere homogenised as the whole brain
homogenate sample, whilst the left hemisphere was separated into
capillary-enriched and capillary-depleted fractions, as above.
Before assay, fractions were sonicated on ice in 12 vols 50 mM
potassium phosphate buffer, pH 7.0, then incubated at 200 lg
protein per assay tube with 3H-DHEAS at 2 nM in the same buffer
in a total volume of 250 lL. In addition to buffer blanks, boiled
blanks (3 min, 100°C) were included for each sample and all
assayed in duplicate. After 3 h at 37°C, incubations were terminated
by the addition of 750 lL 0.1 M NaOH. Free 3H-DHEA was then
extracted twice into 2.0 mL toluene containing non-radioactive
DHEA at 25 lg/mL. This organic phase was dried down for
spotting onto TLC plates, which were developed in solvent system
B. Exposure of the plates to I2 vapour allowed visualisation of the
DHEA spots, which were cut out and placed in scintillation vials
with Ecoscint H for measurement of radioactivity. Production of
DHEA from DHEAS by sulphatase was estimated by subtraction of
the boiled blank for each tissue sample.
Reverse-transcriptase–polymerase chain reaction
Samples were obtained from regions of adult male rat brains
and primary cultures of rat brain microvessel endothelial
cells and astrocytes for extraction of RNA, RT–PCR and
cloning as described in Dolman et al. (2005). At least three
independent samples were tested. The internal control was
b-actin. Reverse transcriptase was omitted from negative
controls. Ampliﬁcation employed 25 cycles for actin and 35
cycles for steroid sulphatase. The PCR products were
separated on 1% agarose gels stained with ethidium bromide,
and visualised with ultraviolet illumination. Sequences of
the primers for steroid sulphatase (accession number
NM012661) were 860–879: CCCAATGAAGTCACCTTT
GC; and 1288–1307: GTGTGAGCCCCTTGTAGTCC;
expected product size 448 bp. For b-actin (accession number
V01217) they were 1343–1363: ATCGTGGGCCGCCCTA
GGCAC and 1652–1673: TGGCCTTAGGGTTCAGAGG
GGC; expected product size 243 bp.
Analysis of results
Brain uptake was calculated as a volume of distribution Vd,
where Vd (lL/g) = (dpm/g tissue)/(dpm/lL perfusate). The
unidirectional transfer coefﬁcients, (Kin,lL/g/min), forDHEAS
and for PregSwere calculated from the Vd at 0.5 min, corrected
with the Vd for the vascular space marker sucrose. Values for
Kin were converted into the permeability–surface area PS
product (lL/g/min) using the Renkin–Crone equation (Renkin
1959; Crone 1963): PS = vF ln (1Kin/vF), where P is the
capillary permeability (cm/min),S is the surface areaof perfused
capillaries (cm2/g), v is the fractional distribution volume of the
tracer in red blood cells (mL/mL), and F is the cerebral blood
ﬂow (mL/g/min). As a saline-based perfusate was used for the
present experiments, vF can be replaced by F, the Kin value for
the ﬂow-limited marker diazepam, estimated from a linear least
squares ﬁt of a plot of Vd against time.
The values for the calculated logarithm of the octanol/
water partition coefﬁcient, Log Poct (cLogPoct), were
obtained from LogKow software (http://www.epa.gov/
oppt/exposure/pubs/episuite.htm).
Film for imaging 3H-activity on TLC plates was visualised
in a Typhoon 9410 Variable Mode phosphorimager for
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analysis with ImageQuant software (Molecular Dynamics,
Amersham, Buckinghamshire, UK).
Statistics
Linear regression lines with conﬁdence limits were ﬁtted in
GraphPad Prism and statistical signiﬁcance of results eval-
uated with Student’s t test or ANOVA, with p < 0.05 accepted
as signiﬁcant and the sample sizes judged to give > 80%
power (http://www.3rs-reduction.co.uk). Rats were allocated
at random to treatments of which the investigators were
aware.
Results
PregS enters the brain more rapidly than DHEAS
Uptake (distribution volume, Vd, in lL/g) was measured at
four time-points, as shown in Fig. 1 for the different brain
regions. For all regions, the initial entry of PregS into the
brain was greater than that of DHEAS and reached a
maximum within 1 min.
When adjusted for perfusate flow rate, different brain
regions show similar permeabilities for steroid sulphates
The regional uptake of DHEAS and PregS after correction
for vascular space is shown in Table 1 as the unidirectional
transfer coefﬁcients at 0.5 min, Kin (lL/g/min). The only
signiﬁcant differences found in Kin were for PregS between
the superior colliculus and medulla and for DHEAS between
the superior colliculus and the cerebellum. However, after
adjustment for perfusate ﬂow rate (using the Kin for
diazepam) and conversion to the permeability–surface area
product (PS), there was no signiﬁcant difference in PS value
for either sulphated steroid between the brain regions
analysed.
Analysis of sulphated steroid BBB permeability
The PS values for PregS and DHEAS were compared with
those for compounds known either to enter the brain
passively or to be substrates for inﬂux or efﬂux transporters
(Qaiser 2004; Youdim et al. 2004). Log PS was plotted
against cLog Poct, an index of lipophilicity (see Fig. 2). For
the passively permeating substances, there is a linear
relation between permeability and lipophilicity. Compounds
known to be substrates for uptake transport lie above and
substrates for efﬂux below this line. For consistency with
the method used for the reference data set, PS values for
DHEAS and PregS were calculated from Kin values
obtained for the slope of a plot of Vd against time from
0.25 to 0.5 min. The log PS values for both PregS and
DHEAS appear below the 95% conﬁdence limits of the line
of best ﬁt for passively permeating compounds, implying
net efﬂux, but not as far below as the known efﬂux
transport substrates colchicine and vinblastine. We therefore
tested the effect of known efﬂux inhibitors on the brain
uptake of PregS and DHEAS.
When the efﬂux transporter inhibitors GF120918
(3 lM; Polli et al. 2004) or MK571 (50 lM; Cisternino
et al. 2003b), alone or in combination, were co-perfused
with either 3H-PregS or 3H-DHEAS there was a signif-
icant decrease in uptake (Fig. 3). Moreover, addition of
the corresponding unlabelled steroid sulphate (0.5 mM)
caused a further decrease in the uptake of 3H-steroid
sulphate.
PregS and DHEAS are rapidly desulphated upon uptake into
the brain
After perfusion with either 3H-PregS or 3H-DHEAS, brains
were homogenised and fractionated into capillary-enriched
(capillary) and capillary-depleted (parenchyma) fractions. The
% recovery of total homogenate radioactivity into these
fractions was as follows (mean  SEM, n = 5 and also shown
as dpm/mg protein): after PregS perfusion 8.8  1.8% (1856
 245 dpm/mg protein) capillary and 68.0  10.0%
(1988  328 dpm/mg protein) parenchyma; after DHEAS
perfusion 2.2  0.3% capillary (3451  511 dpm/mg pro-
tein) and 25.7  2.3% parenchyma (3279  388 dpm/mg
protein). These homogenate fractionswere then extracted prior
to separation of free and conjugated steroids. Extraction
efﬁciencies for total radioactivity from these fractions were as
follows: after PregS perfusion 76.0  2.3% from capillary;
88.7  4.3% from parenchyma and after DHEAS perfusion
80.0  1.3% from capillary; 98.6  8.2% from parenchyma.
Finally, the extracts were separated into free steroid (FS),
steroid glucuronide (SG) and steroid sulphate (SS) fractions by
passage through mixed-mode anion exchange cartridges.
Figure 4 shows the percentage of 3H-label recovered in each
fraction. After perfusion with either 3H-PregS or 3H-DHEAS,
a high proportion of the activity was recovered in the FS
fraction, and for both labels, there was a signiﬁcantly higher
percentage of the free steroid in the parenchyma than in the
brain capillaries. Control experiments (n = 4) in which
standard 3H-DHEAS or 3H-PregS were added to rat brain
homogenates followed by extraction and separation into FS,
SG and SS fractions, conﬁrmed that their rapid desulphation
seen above on brain uptake occurred in vivo and was not an
artefact of the extraction and fractionation procedure (see
Fig. 4 legend). As expected, negligible activity was recovered
as SG and could be accounted for by spill over from the FS
fraction.
After uptake into the brain, DHEAS but not PregS is rapidly
metabolised in both the sulphated and desulphated form
Identities of the steroids present in the FS and SS fractions
from the parenchyma (n = 5) of either 3H-PregS- or 3H-
DHEAS-perfused rat brains were investigated by TLC
alongside both 3H-labelled and non-radioactive standards
(n ≥ 2), the former visualised in a phosphorimager and the
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latter by iodine staining. Positions of these steroids on TLC
are given under Supporting Information (and illustrated in
Figs S2–S6).
Upon TLC, the SS fractions from both 3H-PregS- and
3H-DHEAS-perfused rat brains gave single peaks corre-
sponding to their appropriate standards. Identity of these
sulphated steroids was investigated by eluting the peaks and
desulphating the 3H-label for further TLC as free steroids
alongside standard compounds. Conﬁrmation of the identity
of these free steroids could then be sought by eluting them
for acetylation together with known standards before addi-
tional TLC.
Following desulphation and further TLC, the 3H-label
from the SS fractions of 3H-PregS-perfused rat brains gave a
single peak corresponding with both the desulphated 3H-
PregS and the free Preg standards. Likewise, TLC of the FS
fraction from these 3H-PregS-perfused rat brains in the same
system showed no evidence of metabolism other than
desulphation, with peaks corresponding to standard Preg
and not to other possible Preg metabolites. These putative
(a) (b) (c) (d)
(e) (f) (g) (h)
Fig. 1 Plot of volume of distribution (Vd) against time for uptake of
3H-dehydroepiandrosterone sulphate (DHEAS; ●) and 3H-pregnenolone
sulphate (PregS; ■) into (a) to (g) different regions of the brain plus (h) the Remainder (mean  SEM, n ≥ 3 animals at each time point; error bars
smaller than symbols for DHEAS).
Table 1 Regional unidirectional transfer coefﬁcients, Kin, and permeability (permeability–surface area product, PS) for dehydroepiandrosterone
sulphate (DHEAS) and pregnenolone sulphate (PregS) after 0.5 min perfusion (all in lL/g/min)
Brain region
Vd
Sucrose
Kin
Diazepam
Kin
DHEAS
Kin
PregS
PS
DHEAS
PS
PregS
Sup. colliculus 15.0  0.9 5898.2  1118.4 63.5  6.7† 404.9  30.4* 63.8  6.8 419.6  32.5
Hippocampus 9.9  1.5 4028.8  818.7 45.4  3.4 292.1  24.2 45.6  3.4 303.5  26.0
Striatum 5.6  0.1 2694.6  791.7 47.2  3.9 328.6  41.9 47.6  4.0 351.5  48.1
Hypothalamus 14.6  0.7 2461.2  631.2 57.7  2.7 277.6  48.8 58.4  2.7 295.8  54.8
Parietal cortex 13.6  1.4 1617.6  772.3 38.4  4.5 351.5  9.8 38.7  4.6 377.2  11.3
Cerebellum 12.5  1.4 471.5  193.4 38.6  7.0† 256.8  43.7 40.4  7.6 392.6  103.4
Medulla 9.8  0.3 339.7  147.9 39.4  8.9 196.4  39.5* 42.4  10.0 328.6  117.5
Remainder 10.1  0.8 3363.3  446.2 44.8  4.1 311.2  20.8 45.2  4.1 326.5  22.9
The Kin measurements for DHEAS and PregS have been corrected for vascular space as measured by the Vd for sucrose (in lL/g). Conversion of
these Kin measurements to PS values by the Renkin–Crone equation (see Methods) used the Kin for the ﬂow marker diazepam, as shown. All
values mean  SEM; n ≥ 3. ‘Remainder’ is the brain tissue remaining after the removal of regional samples. p < 0.05 for signiﬁcance of difference
between brain regions after ANOVA as indicated by * and †.
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Preg peaks from the desulphated material of the SS fraction
and from the FS fractions were eluted for acetylation
alongside both 3H-labelled and non-radioactive standard
Preg and other steroids. On subsequent TLC, both standard
3H-Preg and standard desulphated 3H-PregS gave two peaks,
corresponding with those from the acetylated putative Preg
peaks of the FS fractions and of the desulphated SS
fractions. These two peaks arise from a presumed Serini
reaction in which the Preg forms isomeric enol acetates
(Fieser and Huang-Minlon 1949).
From the 3H-DHEAS-perfused rats, there was evidence of
metabolism in both the desulphated SS and the FS fractions,
which each gave two peaks. The earlier peaks from both
fractions corresponded with androstenediol and the later
peaks with 3H-labelled and non-radioactive DHEA. There
were no detectable 7-hydroxymetabolites of DHEA. The two
peaks which arose from the SS fraction were not an artefact
of the deconjugation procedure because desulphation of the
3H-DHEAS standard gave only one peak. Identity of the two
peaks from the SS and the FS fractions was conﬁrmed by
eluting them for acetylation alongside standards for further
TLC. On acetylation, the putative DHEA from both the SS
and the FS fractions corresponded with acetylated standard
3H-labelled DHEA and non-radioactive DHEA. Acetylation
of the putative androstenediol gave peaks from the SS
fractions and from the FS fractions which corresponded with
acetylated standard androstenediol. However, acetylation of
the 3H-label eluted from the putative androstenediol peak in
the FS fraction also gave two additional peaks, one of which
corresponded to standard androstenedione carried through
the acetylation procedure (although this would not be
acetylated) and another which could not be identiﬁed. There
was no 3H-peak corresponding with standard acetylated
testosterone.
Control experiments (n = 4) in which standard 3H-
DHEAS, 3H-DHEA, 3H-PregS or 3H-Preg were added to
rat brain homogenates followed by extraction and separation
into FS and SS fractions, as for the perfused rat brain
samples, then subjected to TLC, showed these labels to be
unchanged by the extraction and separation procedure (see
Supporting Information).
Steroid sulphatase activity is enriched in brain capillaries
In view of the rapid desulphation of both 3H-DHEAS and 3H-
PregS following uptake from the brain perfusate and the higher
Fig. 2 Plot of permeability (Log PS) against calculated lipophilicity
(cLog Poct) for compounds known to enter the brain passively,
compounds known to be substrates for active uptake or efﬂux, and
the two sulphated steroids dehydroepiandrosterone sulphate (DHEAS)
and pregnenolone sulphate (PregS), n ≥ 3 rats for each compound.
Passively permeating compounds are numbered in order of increasing
calculated lipophilicity: 1, Sucrose; 2, Inulin; 3, Mannitol; 4, Glycerol; 5,
Pyridostigmine; 6, Urea; 7, Thiourea; 8, Theophylline; 9, Antipyrine; 10,
Butanol; 11, Naloxone; 12, Physostigmine; 13, Iodo-Antipyrine; 14, DL-
Propanolol. For these passively permeating compounds there is a
signiﬁcant correlation with calculated lipophilicity (p < 0.0001; Spear-
man coefﬁcient = 0.9648). The linear regression line is drawn through
these numbered points, with a slope of 0.5480 and with 95%
conﬁdence limits shown by the dotted lines. Permeability measure-
ments from Youdim et al. (2004) and from (Qaiser 2004).
Fig. 3 Effect of the efﬂux inhibitors GF120918 (3 lM) and MK571
(50 lM), alone or in combination, on the brain uptake of either 3H-
dehydroepiandrosterone sulphate (DHEAS) or 3H-pregnenolone sul-
phate (PregS) after 0.5 min perfusion. The Vd, corrected for sucrose
space (vascular volume), is shown as % control, 32.47  2.03 lL/g for
DHEAS and 165.63  10.40 lL/g for PregS. All values mean  SEM,
n = 3. The effect of 0.5 mM of the corresponding unlabelled steroid
sulphate (SS) in addition to the inhibitors is also shown. The same
p < 0.05 values (ANOVA, with Dunnett’s post hoc test) are indicated for
both DHEAS and PregS; * versus control and † versus GF120918 plus
MK571 alone. The inhibitors GF120918 and MK571 were dissolved in
dimethylsulphoxide to a maximum ﬁnal concentration of 0.8% (v/v) in
the perfusate. Control experiments showed that this vehicle alone did
not cause a change in the uptake (data not shown).
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proportion of free steroid found in the brain parenchyma
compared to the capillary, we assayed these two fractions of
brain for sulphatase activity. Using 3H-DHEAS as the
substrate, sulphatase activity was found to be 5 times higher
in the brain capillary than the brain parenchyma (see Fig. 5a).
Steroid sulphatase mRNA is expressed in brain
Steroid sulphatase mRNA expression was investigated in
brain samples and in cultured rat BBB-related cells. Bands of
the expected size for the steroid sulphatase PCR product
were seen in all the brain regions investigated and in the
samples of primary cultures of brain microvessel endothelial
cells and astrocytes (Fig. 5b). Intensity of bands for b-actin
was similar in all samples. The identity of the products was
conﬁrmed by cloning. There were no bands seen in the
negative controls (results not shown), showing that genomic
DNA was not present.
Discussion
Using direct perfusion with a saline-based solution in situ,
the present study has shown both 3H-labelled steroid
sulphates, PregS and DHEAS, to be taken up and
metabolised by adult male rat brain. We perfused low
concentrations of the steroid sulphates in a saline-based
solution to avoid protein binding and showed uptake of
PregS to be more rapid than for DHEAS, presumably
because of its higher lipophilicity. A large proportion
(> 50%) of both labels was desulphated on uptake, but only
DHEA and DHEAS underwent further metabolism during
the 0.5 min perfusion of our experiments. Further investiga-
tion showed the steroid sulphatase responsible for deconju-
gating PregS and DHEAS to be enriched in the capillaries of
the BBB, and the mRNA for this enzyme to be expressed in
primary cultures of rat brain microvessel endothelial cells
and astrocytes. Conventional light microscope immunohis-
tochemical investigation of steroid sulphatase has revealed
cytoplasmic staining in large neurones of the human cerebral
cortex (Steckelbroeck et al. 2004). Higher resolution tech-
niques will now be necessary to investigate the distribution
of this enzyme in the smaller cells of the BBB.
One previous study (Wang et al. 1997b) showed differ-
ences in PregS concentrations between rat brain regions
following intravenous infusion of this steroid. However, our
results after carotid perfusion show no signiﬁcant difference
in regional permeability for either PregS or DHEAS after
adjustment of regional uptake for perfusate ﬂow. These
measurements of perfusate ﬂow conﬁrm adequate and
physiological perfusion of the brain regions examined and
indicate that with a saline-based perfusion ﬂuid less viscous
than blood, adequate perfusion can be maintained at
pressures (40–70 mm Hg) close to the critical cerebral
perfusion pressure of 50 mm Hg measured in the rat by
Bragin et al. (2014).
Our analysis of BBB permeability suggested a net efﬂux of
these steroid sulphates at the rat BBB, although not as much
with respect to lipophilicity as the known substrates for
efﬂux, colchicine and vinblastine. A net efﬂux of steroid
sulphate from rat brain had been reported by Asaba et al.
(2000) for DHEAS and Hosoya et al. (2000) for estrone
sulphate. Thus, we did not expect the observed decrease in
the uptake of PregS or of DHEAS upon co-perfusion with the
efﬂux transporter inhibitors GF120918 and/or MK571. The
compound GF120918 inhibits P-gp (P-glycoprotein;
ABCB1; ATP-binding cassette transporter B1) and BCRP
(breast cancer resistance protein; ABCG2) (Jonker et al.
2000) whilst MK571 inhibits MRPs (multidrug resistance
associated proteins; ABCCs) (Gekeler et al. 1995). DHEAS
(a)
(b)
Fig. 4 Percentage recoveries of free steroids (FS), steroid glu-
curonides (SG) and steroid sulphates (SS) from capillary and
parenchyma following brain perfusion with (a) 3H-pregnenolone
sulphate (PregS) or (b) 3H-dehydroepiandrosterone sulphate
(DHEAS). All values mean  SEM; n = 5. For signiﬁcance of
difference between capillary and parenchyma: *p < 0.02. Control
experiments in which standard 3H-DHEAS, 3H-DHEA, 3H-PregS or 3H-
Preg were added to rat brain homogenates followed by extraction and
separation as for the samples above showed recovery into free steroid
(FS), steroid glucuronide (SG) and steroid sulphate fractions as
follows. 1). 3H-DHEAS: FS 1.89  0.28%; SG 0.18  0.01%; SS
74.15  0.92%. 2). 3H-DHEA: FS 94.62  0.70%; SG 2.55  0.08%;
SS 0.18  0.01%. 3). 3H-PregS: FS 6.84  0.69%; SG
0.13  0.02%; SS 42.03  1.29%. 4). 3H-Preg: FS 102.01  4.00%;
SG 2.26  0.24%; SS 0.25  0.03%. Further TLC analysis of these
fractions is described under Supporting Information.
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is known to be a substrate for both breast cancer resistance
protein and MRP4 (Suzuki et al. 2003; Zelcer et al. 2003).
In mouse brain, DHEAS uptake increased after systemic
treatment with GF120918 (Lee et al. 2005), but similar
results to ours were obtained by Bourasset et al. (2003),
using the P-gp speciﬁc inhibitor PSC833 (Boesch et al.
1991) in an attempt to inhibit the P-gp mediated efﬂux of
morphine-6-glucuronide, when brain uptake was decreased
rather than increased by PSC833. Thus, the above three
efﬂux inhibitors may not be as speciﬁc as previously thought,
at least at the concentrations used, and may interact with
other transport processes including uptake transporters;
indeed PSC833 has been shown to interact with OATP2
in vitro (Cvetkovic et al. 1999). Finally, we cannot exclude
the possibility that steroid sulphate transport at the abluminal
membrane becomes limiting upon inhibition of steroid
sulphatase and that GF120918 or MK571 are acting as
inhibitors of this enzyme.
Addition of non-radioactive substrate (0.5 mM) to the
GF120918 and MK571 in the perfusion ﬂuid resulted in a
further reduction of the uptake for both radio-labelled steroid
sulphates, providing evidence for the involvement of an
uptake mechanism. Asaba et al. (2000) have implicated
OATP2 (now oatp1a4) in the uptake of DHEAS by rat brain
but, as mentioned above, showed apparent efﬂux across the
BBB to exceed this uptake. The efﬂux of DHEAS is impaired
in oat3-deﬁcient but not oatp1a4-deﬁcient mice (Miyajima
et al. 2011) and oat-3 (organic anion transporter 3) is
expressed at the abluminal membrane of the rat BBB (Mori
et al. 2003). Involvement of anion transporters is further
indicated by the attenuation of DHEAS brain uptake caused by
the aryl sulfamate COUMATE given systemically in the
mouse, even at doses which inhibit steroid sulphatase and
increase the amount of DHEAS in circulation (Nicolas and Fry
2007). The OATPs (organic ion transporting polypeptides)
and OATs (organic ion transporters) act as bidirectional
transporters and may therefore be involved in uptake and/or
efﬂux. New members of these families have recently been
identiﬁed at the BBB (see Sugiyama et al. 2003; Tachikawa
et al. 2014; Nigam et al. 2015) and an overlap of substrates
and differences in expression between species are becoming
apparent.
Further investigations are required to identify the trans-
porters responsible for the inﬂux and efﬂux of steroid
sulphates across the BBB and to characterise their saturation
kinetics. In this regard, the rapid and extensive (> 50%)
desulphation of both PregS and DHEAS seen on crossing the
BBB in the present study will presumably alter their
concentration gradients in favour of inﬂux. Moreover, the
present results indicate that, even if there is a net efﬂux of the
sulphated steroid, there will be an overall gain of free steroid
into the brain. This interpretation is supported by the higher
proportion of free than sulphated steroid accumulating in the
brain parenchyma as opposed to the capillary fraction
following perfusion through the carotid artery. This contrasts
with results reported after intracerebral injection of DHEAS
in rats, when Kishimoto and Hoshi (1972) found a higher
proportion of sulphated than free steroid in blood plasma and
Asaba et al. (2000) reported 90% of the 3H-label appearing
in the jugular vein after intracerebral 3H-DHEAS to be the
unchanged steroid sulphate. Thus, the free steroid liberated
by deconjugation of the steroid sulphates upon uptake across
the BBB is likely to be retained by the brain. There have
been few reports of transport of PregS at the BBB, so the
similarities that we have demonstrated between DHEAS and
PregS are of interest. In humans, the most likely
Fig. 5 Steroid sulphatase activity is enriched in the blood–brain barrier and its mRNA expressed in rat brain. (a) Steroid sulphatase activity assayed
with 3H-dehydroepiandrosterone sulphate as the substrate in fractions of capillary, parenchyma and whole homogenate of rat brain. All values
mean  SEM, n = 6; *p < 0.001 in comparison to parenchyma. (b) Expression of mRNA for steroid sulphatase (upper pane) and b-actin (lower
pane) in rat brain samples; the expected band sizes in base pairs (bp) for PCR products are as shown: Cx, cortex; Mb, midbrain; Hp, hippocampus;
RBEC, cultured rat brain microvessel endothelial cells; As, cultured rat astrocytes.
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physiological conditions for net uptake of free steroid into
brain are from DHEAS when this steroid reaches its highest
plasma concentration in young adulthood (Orentreich et al.
1984) and from PregS (and 17a-hydroxypregnenolone
sulphate) during pregnancy (Vcelakova et al. 2007).
Consistent with the lack of CYP17 activity in the brain
(see Introduction), the present investigation revealed no
detectable conversion of either PregS or the deconjugated
free steroid to the 17a-hydroxy derivative or onwards to
DHEA(S) (see Fig. 6), a major metabolic pathway in the
periphery (Vcelakova et al. 2007). Previous analyses of
endogenous brain steroids have also failed to detect the 17a-
hydroxypregnenolone intermediate which would be formed
if CYP17 was catalysing the conversion of Preg to DHEA in
this tissue (Ebner et al. 2006). Indeed, the free Preg
generated from brain uptake of PregS did not undergo any
detectable further metabolism during the 0.5 min perfusion
of our experiments. However, enzymes which convert Preg
to progesterone and further reduced metabolites are known to
be active in rat brain (see Ebner et al. 2006) and presumably
generate the increased brain progesterone, 5a-dihydropro-
gesterone and allopregnanolone seen 20 min after intra-
venous infusion of PregS by Cheney et al. (1995).
Allopregnanolone is a potent sedative steroid (see Melcangi
and Panzica 2014) but varying amounts of the parent PregS
in brain following systemic administration of this excitatory
steroid sulphate (see Introduction) could account for its
variable interactions with barbiturate-induced anaesthesia
(Majewska et al. 1989; Wang et al. 1997a).
Unlike PregS and as shown schematically in Fig 6,
DHEAS underwent metabolism in brain both before and
after desulphation during the 0.5 min perfusion of the present
study. Thus, both DHEA and its 17b-hydroxylated metabo-
lite androstenediol could be identiﬁed in the free steroid and
the steroid sulphate fractions following perfusion with
DHEAS. Comparable results were obtained in rat brain by
Kishimoto and Hoshi (1972) following intracardiac injection
of DHEAS. Also, Kishimoto (1973) demonstrated a rat brain
microsomal enzyme activity which could 17b-hydroxylate
both DHEA and DHEAS. The 17b-hydroxysteroid:NAD(P)+
oxidoreductase (EC 1.1.1.51) which would catalyse this
conversion appears to be localised in astrocytes in rat brain
(Pelletier et al. 1995) and would account for the rapid
formation of androstenediol sulphate as DHEAS is taken up
at the BBB. The present study has also shown further
metabolism of DHEA in the free steroid fraction to
androstenedione. However, there was no evidence for
production of 7a-hydroxy DHEA, the major DHEA
Fig. 6 Pathways of pregnenolone sulphate and dehydroepiandrosterone sulphate metabolism after uptake into adult male rat brain. Metabolites
identiﬁed in the present study are shown in black and those possible but not identiﬁed shown in red. Enzyme activity is indicated by dotted lines with
the following abbreviations: CYP17, 17-hydroxylase/c17,20-lyase (EC 1.14.99.9); 3b-HSD,3b-hydroxy-D5-steroid:NAD+ 3-oxidoreductase (EC
1.1.1.145); 17b-HSD, 17b-hydroxysteroid:NAD(P)+ oxidoreductase (EC 1.1.1.51); STS, steroid sulphatase (EC 3.1.6.2). Enzymes previously
identiﬁed by others are shown in black and, again, activity not found shown in red.
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metabolite of rat brain microsomes in vitro (Akwa et al.
1992). Further studies are necessary to identify the metabo-
lites of PregS and DHEAS following uptake at the BBB and
their likely sites of action but, as mentioned above, enzymes
exist in brain to convert free Preg to progesterone and
sedative steroids. As for the DHEA, androstenediol and
androstenedione formed from DHEAS, these are androgenic
(Mo et al. 2006) and could also be further metabolised to
estrogens. The latter conversion would require aromatase
activity, which has been shown to enhance the neuroprotec-
tive effects of DHEAS in the rat (Juhasz-Vedres et al. 2006).
If at least part of the action of circulating DHEAS on the
brain requires conversion to estrogens, then this may explain
why its ability to enhance the acquisition and consolidation
of memory in young laboratory animals is greater in males
than in females, with their higher endogenous levels of
estrogens (Sujkovic et al. 2012). Conversely, after the
menopause in women, when ovarian secretion of estrogens
has ceased and plasma DHEAS is declining with age more
rapidly than in men (Orentreich et al. 1984), there is no
gonadal source of androgens for conversion to estrogens and
so females should be more sensitive to DHEA(S) supple-
mentation than males (see Labrie 2010). This may account
for the ability of short-term (2 week) DHEA supplementa-
tion in elderly human subjects to improve mood and well-
being (but not cognitive function) in women rather than men
(Wolf et al. 1997). Another possibility is for aromatase-
independent actions of DHEAS via androstenediol at estro-
gen receptor-b (see Baker 2013; Warner and Gustafsson
2015). Whatever the central mechanism, the present results
suggest that supplementation with DHEAS rather than
DHEA may be a more effective way of boosting androgen
concentrations in the ageing brain.
In their classic paper, Corpechot et al. (1981) suggested
designation of DHEAS as a neurosteroid on the grounds that it
persisted in adult male brain 15 days after adrenalectomy and
castration, thereby indicating accumulation and/or synthesis
within this tissue. Subsequent work (see Baulieu and Robel
1990; Asaba et al. 2000; Sujkovic et al. 2009;Miyajima et al.
2011) has argued against the accumulation ofDHEAS because
it is cleared from brain more rapidly than the 15 days of the
Corpechot et al. (1981) study and yet, as summarised in the
Introduction, the evidence remains equivocal for the synthesis
of DHEA(S) within this tissue. The present results document a
rapid uptake and desulphation of DHEAS at the BBB which
accounts for the presence of this conjugate and its free steroid
in adult rat brain. Our results are not inconsistent with those of
Corpechot et al. (1981), who reported the concentration of
DHEAS in the adult male rat plasma to remain unchanged
15 days after adrenalectomy and castration. Moreover, we
have shown the desulphation of DHEAS and of PregS to be
enriched in the BBB, which must play a key role in regulating
not only the effects of these neuroactive steroids themselves
but also their function as hormone precursors, giving rise to
free steroids within the brain. Integrating the permeability and
transport properties of the BBB with the metabolic pathways
operating within the CNS gives a more complete understand-
ing of the action of neuroactive steroids, building on the
concept of the intracrinology of the protected CNS microen-
vironment beyond the BBB.
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Figure S1. Two examples of phosphor images from TLC plates
showing the purity of 3H-dehydroepiandrosterone (DHEAS) and of
3H-pregnenolone sulphate (PregS).
Figure S2. Typical proﬁles of radioactivity (Intensity in arbitrary
units (au)), following TLC of the steroid sulphate fraction from the
parenchyma of rat brains perfused with (a) 3H-dehydroepiandroster-
one sulphate (3H-DHEAS) or (b) 3H-pregnenolone sulphate.
Figure S3. Typical proﬁles of radioactivity in arbitrary units (au)
following TLC of (b) the desulphated steroid sulphate fraction and
(c) the free steroid fraction from the parenchyma of rat brains
perfused with 3H-pregnenolone sulphate. Chromatography was in
solvent system B and the positions of steroid standards indicated in
panel (a) above the proﬁles.
Figure S4. Example proﬁles of radioactivity following TLC of
the acetylated putative pregnenolone yielded by previous TLC (see
Fig. S3) of either (b) the desulphated steroid sulphate fraction or (c)
the free steroid fraction of the brain parenchyma of a rat perfused
with 3H-pregnenolone sulphate.
Figure S5. Typical proﬁles of radioactivity in arbitrary units (au)
following TLC of (b) the desulphated steroid sulphate fraction and
(c) the free steroid fraction from the parenchyma of rat brains
perfused with 3H-dehydroepiandrosterone sulphate (DHEAS)
Figure S6. Example proﬁles of radioactivity in arbitrary units
(au) following TLC of the acetylated putative dehydroepiandros-
terone (DHEA; b and d) or androstenediol (c and e) yielded by prior
TLC (see Fig. S5) of either the desulphated steroid sulphate fraction
(b and c) or the free steroid fraction (d and e) from the parenchyma
of rat brains perfused with 3H-DHEAS.
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